# KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

> **NCT01626664** · PHASE2 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Adult T-cell Leukemia-Lymphoma

## Interventions

- **BIOLOGICAL:** KW-0761
- **DRUG:** Pralatrexate
- **DRUG:** gemcitabine plus oxaliplatin
- **DRUG:** DHAP

## Key facts

- **NCT ID:** NCT01626664
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-08
- **Final completion:** 2018-02
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626664, "KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01626664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*